Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Recipharm AB (publ)    RECI B   SE0005757267

RECIPHARM AB (PUBL)

(RECI B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
150.3(c) 149.2(c) 152.3(c) 157.1(c) 155.6(c) Last
191 793 145 505 127 564 737 356 331 232 Volume
-0.07% -0.73% +2.08% +3.15% -0.95% Change
More quotes
Financials
Sales 2020 11 166 M 1 316 M 1 316 M
Net income 2020 222 M 26,1 M 26,1 M
Net Debt 2020 8 743 M 1 030 M 1 030 M
P/E ratio 2020 67,2x
Yield 2020 0,94%
Sales 2021 11 603 M 1 368 M 1 368 M
Net income 2021 531 M 62,6 M 62,6 M
Net Debt 2021 7 802 M 919 M 919 M
P/E ratio 2021 29,5x
Yield 2021 1,25%
Capitalization 15 692 M 1 842 M 1 849 M
EV / Sales 2020 2,19x
EV / Sales 2021 2,02x
Nbr of Employees -
Free-Float 71,3%
More Financials
Company
Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among others; and Development... 
Sector
Pharmaceuticals
Calendar
02/19 | 01:45amEarnings Release
More about the company
Notations Surperformance© of Recipharm AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about RECIPHARM AB (PUBL)
09:56aRECIPHARM : announces signature of letter of intent for aseptic fill-finish manu..
AQ
04:30aRECIPHARM : to produce some of Moderna's COVID-19 vaccine in France
RE
11/24MODERNA : Sweden's Recipharm signs deal to package Moderna's COVID-19 vaccine
RE
11/24RECIPHARM : announces signature of letter of intent for aseptic fill-finish manu..
PU
11/24RECIPHARM : announces signature of letter of intent for aseptic fill-finish manu..
AQ
11/18RECIPHARM : and Medspray establish joint venture to exploit novel softmist techn..
AQ
11/17RECIPHARM : and Medspray establish joint venture to exploit novel softmist techn..
PU
11/17RECIPHARM : and Medspray establish joint venture to exploit novel softmist techn..
AQ
11/11RECIPHARM : invests in its pMDI valves production capacity
AQ
11/10RECIPHARM : invests in its pMDI valves production capacity
PU
11/10RECIPHARM : invests in its pMDI valves production capacity
AQ
11/05RECIPHARM : publishes its interim report for the third quarter 2020
PU
11/05RECIPHARM AB : publishes its interim report for the third quarter 2020
AQ
11/03RECIPHARM AB : - Invitation to the presentation of Recipharm's interim report fo..
AQ
11/02RECIPHARM : Invitation to the presentation of Recipharm's interim report for the..
PU
More news
News in other languages on RECIPHARM AB (PUBL)
2019CONSORT MEDICAL PLC : Consort Medical accepte l'offre du Suédois Recipharm AB
2019RECIPHARM AB (PUBL) : Veröffentlichung des Quartalsergebnisses
2019RECIPHARM AB (PUBL) : publication des résultats trimestriels
2019RECIPHARM AB (PUBL) : Veröffentlichung des Jahresergebnisses
2019RECIPHARM AB (PUBL) : publication des résultats annuels
More news
Chart RECIPHARM AB (PUBL)
Duration : Period :
Recipharm AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECIPHARM AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 163,00 SEK
Last Close Price 155,60 SEK
Spread / Highest target 11,2%
Spread / Average Target 4,76%
Spread / Lowest Target -10,7%
EPS Revisions
Managers
NameTitle
Thomas Bengt Eldered Chief Executive Officer & Director
Lars Rickard Backsell Chairman
Tobias Hägglöv Chief Financial Officer
Per Anders Gustav Carlberg Independent Director
Marianne Dicander Alexandersson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RECIPHARM AB (PUBL)19.76%1 849
MERCK KGAA24.06%67 521
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD93.16%19 782
KYOWA KIRIN CO., LTD.9.13%14 477
BETTA PHARMACEUTICALS CO., LTD.38.66%5 960
YUHAN CORPORATION35.94%3 707